<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">antibiotics-664</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Новые данные о молекулярных мишенях тамоксифена, отличных от рецепторов эстрогенов, и их клиническая значимость</article-title><trans-title-group xml:lang="en"><trans-title>New Data on Molecular Targets of Tamoxifen Besides Estrogen Receptors, Their Clinical Significancy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богуш</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogush</surname><given-names>T. A.</given-names></name></name-alternatives><email xlink:type="simple">bogush@orc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полежаев</surname><given-names>Б. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Polezhaev</surname><given-names>B. B.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дудко</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dudko</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богуш</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogush</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кирсанов</surname><given-names>В. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kirsanov</surname><given-names>V. Yu.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полоцкий</surname><given-names>Б. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Polotsky</surname><given-names>B. E.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тюляндин</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tjuljandin</surname><given-names>S. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давыдов</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Davydov</surname><given-names>M. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N. N. Blokhin Russian Cancer Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>M. V. Lomonosov Moscow State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>13</day><month>05</month><year>2020</year></pub-date><volume>61</volume><issue>3-4</issue><fpage>41</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Богуш Т.А., Полежаев Б.Б., Дудко Е.А., Богуш Е.А., Кирсанов В.Ю., Полоцкий Б.Е., Тюляндин С.А., Давыдов М.И., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Богуш Т.А., Полежаев Б.Б., Дудко Е.А., Богуш Е.А., Кирсанов В.Ю., Полоцкий Б.Е., Тюляндин С.А., Давыдов М.И.</copyright-holder><copyright-holder xml:lang="en">Bogush T.A., Polezhaev B.B., Dudko E.A., Bogush E.A., Kirsanov V.Y., Polotsky B.E., Tjuljandin S.A., Davydov M.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/664">https://www.antibiotics-chemotherapy.ru/jour/article/view/664</self-uri><abstract><p>Тамоксифен - первый таргетный препарат, который по-прежнему занимает лидирующую позицию в лечении рака молочной железы. Экспериментальные работы последних лет раскрывают всё новые и новые биологические эффекты при воздействии тамоксифена на опухолевые клетки. Данная публикация является продолжением опубликованного в 2012 г. обзора данных литературы, демонстрирующих многообразие эффектов тамоксифена, не связанных с его взаимодействием с рецепторами эстрогенов. Так, выявлен обширный спектр мишеней препарата, которые являются ключевыми точками сигнальных каскадов, активирующих пролиферацию клеток, определяют агрессивность течения опухолевого процесса и чувствительность к химиотерапии. Описаны клинические исследования применения тамоксифена, основанием для которых явилось воздействие препарата на мишени, отличные от рецепторов эстрогенов. Кроме того, в обзор включены данные о противовирусной, противобактериальной, противогрибковой и противопаразитарной активности тамоксифена.</p></abstract><trans-abstract xml:lang="en"><p>Tamoxifen is the first target agent with a high-end position in breast cancer therapy till now. In recent years experimental researches revealed new biological effects of tamoxifen on tumor cells. The present study continues the theme of the review published in 2012, where a plenty of tamoxifen effects besides interaction with estrogen receptors was discussed. Thus, there is described a wide range of the drug targets which are the key points of signal cascades activating the cell proliferation and determining the course of the growth of the cancer and its sensitivity to chemotherapy. Also clinical trials of tamoxifen based on existing of targets besides the estrogen receptors are reviewed. Furthermore, the data on the antiviral, antibacterial, antifungal and antiparasitic activities of tamoxifen are indicated.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тамоксифен</kwd><kwd>протеинкиназа С</kwd><kwd>апоптоз</kwd><kwd>антиангиогенное действие</kwd><kwd>метастазирование</kwd><kwd>лекарственная устойчивость</kwd><kwd>противоопухолевое действие</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tamoxifen</kwd><kwd>protein kinase C</kwd><kwd>apoptosis</kwd><kwd>antiangiogenic action</kwd><kwd>metastasis</kwd><kwd>drug resistance</kwd><kwd>anticancer action</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bogush T., Dudko E., Bogush E. et al. Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev2012; 6: 2: e15.</mixed-citation><mixed-citation xml:lang="en">Bogush T., Dudko E., Bogush E. et al. Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev2012; 6: 2: e15.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Balça-Silva J., Matias D., do Carmo A. et al. Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines. Biochim Biophysic Acta 2015; 1850: 4: 722-732.</mixed-citation><mixed-citation xml:lang="en">Balça-Silva J., Matias D., do Carmo A. et al. Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines. Biochim Biophysic Acta 2015; 1850: 4: 722-732.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yang L., Yuan X., Wang J. et al. Radiosensitization of human glioma cells by tamoxifen is associated with the inhibition of PKC-i activity in vitro. Oncol Lett 2015; 10: 1: 473-478.</mixed-citation><mixed-citation xml:lang="en">Yang L., Yuan X., Wang J. et al. Radiosensitization of human glioma cells by tamoxifen is associated with the inhibition of PKC-i activity in vitro. Oncol Lett 2015; 10: 1: 473-478.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Couldwell W.T., Hinton D.R., Surnock A.A. et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clinical cancer research: an Official J American Association for Cancer Research 1996; 2: 4: 619-622.</mixed-citation><mixed-citation xml:lang="en">Couldwell W.T., Hinton D.R., Surnock A.A. et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clinical cancer research: an Official J American Association for Cancer Research 1996; 2: 4: 619-622.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chamberlain M.C., Kormanik P.A. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 1999; 56: 6: 703-708.</mixed-citation><mixed-citation xml:lang="en">Chamberlain M.C., Kormanik P.A. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 1999; 56: 6: 703-708.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mastronardi L., Puzzilli F., Couldwell W. T. et al. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neuro-Oncol 1998; 38: 1: 59-68.</mixed-citation><mixed-citation xml:lang="en">Mastronardi L., Puzzilli F., Couldwell W. T. et al. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neuro-Oncol 1998; 38: 1: 59-68.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tang P., Roldan G., Brasher P. M. et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neuro-Oncol 2006; 78: 3: 311-316.</mixed-citation><mixed-citation xml:lang="en">Tang P., Roldan G., Brasher P. M. et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neuro-Oncol 2006; 78: 3: 311-316.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cristofori A., Carrabba G., Lanfranchi G. et al. Continuous tamoxifen and dose-dense temozolamide in recurrent glioblastoma. Anticancer Res 2013; 33: 8: 3383-3389.</mixed-citation><mixed-citation xml:lang="en">Cristofori A., Carrabba G., Lanfranchi G. et al. Continuous tamoxifen and dose-dense temozolamide in recurrent glioblastoma. Anticancer Res 2013; 33: 8: 3383-3389.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kohli L., Kaza N., Coric T. et al. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res 2013; 73: 14: 4395-4405.</mixed-citation><mixed-citation xml:lang="en">Kohli L., Kaza N., Coric T. et al. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res 2013; 73: 14: 4395-4405.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Xie X., Wu M. Y., Shou L. M. et al. Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway. Oncol Lett 2015; 9: 2: 837-844.</mixed-citation><mixed-citation xml:lang="en">Xie X., Wu M. Y., Shou L. M. et al. Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway. Oncol Lett 2015; 9: 2: 837-844.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Keating J.J., Johnson P.J., Cochrane A.M. et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Brit J Cancer 1989; 60: 5: 789-792.</mixed-citation><mixed-citation xml:lang="en">Keating J.J., Johnson P.J., Cochrane A.M. et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Brit J Cancer 1989; 60: 5: 789-792.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Theve N.O., Pousette A., Carlström K. Adenocarcinoma of the pancreas-a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol 1983; 9: 3: 193-197.</mixed-citation><mixed-citation xml:lang="en">Theve N.O., Pousette A., Carlström K. Adenocarcinoma of the pancreas-a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol 1983; 9: 3: 193-197.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wong A., Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer 1993; 71: 7: 2200-2203.</mixed-citation><mixed-citation xml:lang="en">Wong A., Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer 1993; 71: 7: 2200-2203.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Morita S., Motohara T., Ogawa K., Horimi T. Hormone therapy using tamoxifen in unresectable carcinoma of the pancreas-preliminary study. Nihon Igaku Höshasen Gakkai zasshi. Nipp Acta Radiol 1992; 52: 12: 1686-1688.</mixed-citation><mixed-citation xml:lang="en">Morita S., Motohara T., Ogawa K., Horimi T. Hormone therapy using tamoxifen in unresectable carcinoma of the pancreas-preliminary study. Nihon Igaku Höshasen Gakkai zasshi. Nipp Acta Radiol 1992; 52: 12: 1686-1688.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lamy R., Conroy T., Brunaud L., Bresler L. Tamoxifen for metastatic pancreatic adenocarcinoma: a complete response. Gastroenterol Clin Biol 2001; 25: 10: 912-913.</mixed-citation><mixed-citation xml:lang="en">Lamy R., Conroy T., Brunaud L., Bresler L. Tamoxifen for metastatic pancreatic adenocarcinoma: a complete response. Gastroenterol Clin Biol 2001; 25: 10: 912-913.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wenger F.A., Zieren H.U., Jacobi C.A., Müller J.M. Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen. Langenbecks Archiv Für Chirurgie. Supplement. Kongressband 1998; 115: 1348-1350.</mixed-citation><mixed-citation xml:lang="en">Wenger F.A., Zieren H.U., Jacobi C.A., Müller J.M. Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen. Langenbecks Archiv Für Chirurgie. Supplement. Kongressband 1998; 115: 1348-1350.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenberg L., Barkun A.N., Denis M.H., Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995; 75: 1: 23-28.</mixed-citation><mixed-citation xml:lang="en">Rosenberg L., Barkun A.N., Denis M.H., Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995; 75: 1: 23-28.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Patel B.M., Desai V.J. Beneficial role of tamoxifen in experimentally induced cardiac hypertrophy. Pharmacol Reports 2014; 66: 2: 264-272.</mixed-citation><mixed-citation xml:lang="en">Patel B.M., Desai V.J. Beneficial role of tamoxifen in experimentally induced cardiac hypertrophy. Pharmacol Reports 2014; 66: 2: 264-272.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo J.R., Wang C.C., Huang S.K., Wang S.J. Tamoxifen depresses glutamate release through inhibition of voltage-dependent Ca2+ entry and protein kinase Ca in rat cerebral cortex nerve terminals. Neurochem Internation 2012; 60: 2: 105-114.</mixed-citation><mixed-citation xml:lang="en">Kuo J.R., Wang C.C., Huang S.K., Wang S.J. Tamoxifen depresses glutamate release through inhibition of voltage-dependent Ca2+ entry and protein kinase Ca in rat cerebral cortex nerve terminals. Neurochem Internation 2012; 60: 2: 105-114.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Steckert A.V., Valvassori S.S., Mina F. et al. Protein kinase C and oxidative stress in an animal model of mania. Curr Neurovascul Res 2012; 9: 1: 47-57.</mixed-citation><mixed-citation xml:lang="en">Steckert A.V., Valvassori S.S., Mina F. et al. Protein kinase C and oxidative stress in an animal model of mania. Curr Neurovascul Res 2012; 9: 1: 47-57.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Armani F., Andersen M. L., Galduróz J.C. Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology 2014; 231: 4: 639-649.</mixed-citation><mixed-citation xml:lang="en">Armani F., Andersen M. L., Galduróz J.C. Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology 2014; 231: 4: 639-649.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Smith C.P., Oh J.D., Bibbiani F. et al. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology 2007; 52: 2: 515-526.</mixed-citation><mixed-citation xml:lang="en">Smith C.P., Oh J.D., Bibbiani F. et al. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology 2007; 52: 2: 515-526.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Li Z, Wang N., Fang J. et al. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Oncol Reports 2012; 27: 6: 1879-1886. Выполнено при поддержке РФФИ (гранты 15-04-06991-а и 16-34-01049-мол-а) и гранта Президента Российской Федерации МК-7709.2016.7.</mixed-citation><mixed-citation xml:lang="en">Li Z, Wang N., Fang J. et al. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Oncol Reports 2012; 27: 6: 1879-1886. Выполнено при поддержке РФФИ (гранты 15-04-06991-а и 16-34-01049-мол-а) и гранта Президента Российской Федерации МК-7709.2016.7.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Shim J.S., Li R. J., Lv J. et al. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism. Cancer Lett 2015; 362: 1: 106-115.</mixed-citation><mixed-citation xml:lang="en">Shim J.S., Li R. J., Lv J. et al. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism. Cancer Lett 2015; 362: 1: 106-115.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Garvin S., Nilsson U.W., Dabrosin C. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Brit J Cancer 2005; 93: 9: 1005-1010.</mixed-citation><mixed-citation xml:lang="en">Garvin S., Nilsson U.W., Dabrosin C. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Brit J Cancer 2005; 93: 9: 1005-1010.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Morad S.A., Cabot M.C. Tamoxifen regulation of sphingolipid metabolism-therapeutic implications. Biochim Biophys Acta 2015; 1851: 9: 1134-1145.</mixed-citation><mixed-citation xml:lang="en">Morad S.A., Cabot M.C. Tamoxifen regulation of sphingolipid metabolism-therapeutic implications. Biochim Biophys Acta 2015; 1851: 9: 1134-1145.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Morad S.A., Madigan J.P., Levin J.C. et al. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochem Pharmacol 2013; 85: 8: 1057-1065.</mixed-citation><mixed-citation xml:lang="en">Morad S.A., Madigan J.P., Levin J.C. et al. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochem Pharmacol 2013; 85: 8: 1057-1065.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ribeiro M.P., Santos A.E., Custodio J.B. Mitochondria: the gateway for tamoxifen-induced liver injury. Toxicology 2014; 323: 10-18.</mixed-citation><mixed-citation xml:lang="en">Ribeiro M.P., Santos A.E., Custodio J.B. Mitochondria: the gateway for tamoxifen-induced liver injury. Toxicology 2014; 323: 10-18.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Li Z., Chen J., Lei T., Zhang H. Tamoxifen induces apoptosis of mouse microglia cell line BV-2 cells via both mitochondrial and death receptor pathways. J Huazhong Univer Science Technol. Medical Sciences 2012; 32: 2: 221-226.</mixed-citation><mixed-citation xml:lang="en">Li Z., Chen J., Lei T., Zhang H. Tamoxifen induces apoptosis of mouse microglia cell line BV-2 cells via both mitochondrial and death receptor pathways. J Huazhong Univer Science Technol. Medical Sciences 2012; 32: 2: 221-226.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Todorova V.K., Kaufmann Y., Luo S., Klimberg V.S. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol 2011; 67: 2: 285-291.</mixed-citation><mixed-citation xml:lang="en">Todorova V.K., Kaufmann Y., Luo S., Klimberg V.S. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol 2011; 67: 2: 285-291.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang J.J., Kim H.N., Kim J. et al. Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. BioMetals 2010; 23: 6: 997-1013.</mixed-citation><mixed-citation xml:lang="en">Hwang J.J., Kim H.N., Kim J. et al. Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. BioMetals 2010; 23: 6: 997-1013.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Cho K.S., Yoon Y.H., Choi J.A. et al. Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells. Invest Ophthalmol Visual Sci 2012; 53: 9: 5344-5353.</mixed-citation><mixed-citation xml:lang="en">Cho K.S., Yoon Y.H., Choi J.A. et al. Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells. Invest Ophthalmol Visual Sci 2012; 53: 9: 5344-5353.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Prather P.L., FrancisDevaraj F., Dates C.R. et al. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochem Biophys Res Com 2013; 441: 2: 339-343.</mixed-citation><mixed-citation xml:lang="en">Prather P.L., FrancisDevaraj F., Dates C.R. et al. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochem Biophys Res Com 2013; 441: 2: 339-343.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Herrera J.L., Diaz M., Hernandez-Fernaud J.R. et al. Voltage-dependent anion channel as a resident protein of lipid rafts: post-transductional regulation by estrogens and involvement in neuronal preservation against Alzheimer's disease. J Neurochem 2011; 116: 5: 820-827.</mixed-citation><mixed-citation xml:lang="en">Herrera J.L., Diaz M., Hernandez-Fernaud J.R. et al. Voltage-dependent anion channel as a resident protein of lipid rafts: post-transductional regulation by estrogens and involvement in neuronal preservation against Alzheimer's disease. J Neurochem 2011; 116: 5: 820-827.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Pawar P., Ma L., Byon C.H. et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res: Official J Amer Assoc Cancer Res 2009; 15: 4: 1288-1296.</mixed-citation><mixed-citation xml:lang="en">Pawar P., Ma L., Byon C.H. et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res: Official J Amer Assoc Cancer Res 2009; 15: 4: 1288-1296.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Jing G., Yuan K., Turk A.N. et al. Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis. Lab Investigat; J Techn Meth Pathol 2011; 91: 6: 896-904.</mixed-citation><mixed-citation xml:lang="en">Jing G., Yuan K., Turk A.N. et al. Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis. Lab Investigat; J Techn Meth Pathol 2011; 91: 6: 896-904.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Cimica V., Smith M.E., Zhang Z. et al. Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer 2010; 10: 634.</mixed-citation><mixed-citation xml:lang="en">Cimica V., Smith M.E., Zhang Z. et al. Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer 2010; 10: 634.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Perez B., Henriquez C., Sarmiento J. et al. Tamoxifen as a new therapeutic tool for neutrophilic lung inflammation. Respirology 2016; 21: 1: 112-118.</mixed-citation><mixed-citation xml:lang="en">Perez B., Henriquez C., Sarmiento J. et al. Tamoxifen as a new therapeutic tool for neutrophilic lung inflammation. Respirology 2016; 21: 1: 112-118.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Sarmiento J., Perez B., Morales N. et al. Apoptotic effects of tamoxifen on leukocytes from horse peripheral blood and bronchoalveolar lavage fluid. Vet Res Com 2013; 37: 4: 333-338.</mixed-citation><mixed-citation xml:lang="en">Sarmiento J., Perez B., Morales N. et al. Apoptotic effects of tamoxifen on leukocytes from horse peripheral blood and bronchoalveolar lavage fluid. Vet Res Com 2013; 37: 4: 333-338.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Mao J., Yuan J., Wang L. et al. Tamoxifen inhibits migration of estrogen receptor-negative hepatocellular carcinoma cells by blocking the swelling-activated chloride current. J Cell Physiol 2013; 228: 5: 991-1001.</mixed-citation><mixed-citation xml:lang="en">Mao J., Yuan J., Wang L. et al. Tamoxifen inhibits migration of estrogen receptor-negative hepatocellular carcinoma cells by blocking the swelling-activated chloride current. J Cell Physiol 2013; 228: 5: 991-1001.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Ribeiro M.P., Silva F.S., Paixâo J. et al. The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells. Europ J Pharmacol 2013; 715: 1-3: 354-362.</mixed-citation><mixed-citation xml:lang="en">Ribeiro M.P., Silva F.S., Paixâo J. et al. The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells. Europ J Pharmacol 2013; 715: 1-3: 354-362.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Mao Z., Zhou J., Luan J. et al. Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells. Biomed Pharmacother 2014; 68: 2: 179-183.</mixed-citation><mixed-citation xml:lang="en">Mao Z., Zhou J., Luan J. et al. Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells. Biomed Pharmacother 2014; 68: 2: 179-183.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Nicolao M.C., Elissondo M.C. et al. In vitro and in vivo effects of tamoxifen against larval stage Echinococcus granulosus. Antimicrob Agents Chemother 2014; 58: 9: 5146-5154.</mixed-citation><mixed-citation xml:lang="en">Nicolao M.C., Elissondo M.C. et al. In vitro and in vivo effects of tamoxifen against larval stage Echinococcus granulosus. Antimicrob Agents Chemother 2014; 58: 9: 5146-5154.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Miguel D.C., Yokoyama-Yasunaka J.K., Andreoli W.K. et al. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of para-sitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother 2007; 60: 3: 526-534.</mixed-citation><mixed-citation xml:lang="en">Miguel D.C., Yokoyama-Yasunaka J.K., Andreoli W.K. et al. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of para-sitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother 2007; 60: 3: 526-534.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Miguel D.C., Zauli-Nascimento R.C., Yokoyama-Yasunaka J.K. et al. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother 2009; 63: 2: 365-368.</mixed-citation><mixed-citation xml:lang="en">Miguel D.C., Zauli-Nascimento R.C., Yokoyama-Yasunaka J.K. et al. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother 2009; 63: 2: 365-368.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Butts A., Koselny K., Chabrier-Rosello Y. et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio 2014; 5: 1: e00765-00713.</mixed-citation><mixed-citation xml:lang="en">Butts A., Koselny K., Chabrier-Rosello Y. et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio 2014; 5: 1: e00765-00713.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X., Fang Y., Jaiseng W. et al. Characterization of tamoxifen as an antifungal agent using the yeast Schizosaccharomyces pombe model organism. Kobe J Med Sci 2015; 61: 2: E54-63.</mixed-citation><mixed-citation xml:lang="en">Zhang X., Fang Y., Jaiseng W. et al. Characterization of tamoxifen as an antifungal agent using the yeast Schizosaccharomyces pombe model organism. Kobe J Med Sci 2015; 61: 2: E54-63.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Jang W.S., Kim S., Podder B. et al. Anti-mycobacterial activity of tamoxifen against drug-resistant and intra-macrophage Mycobacterium tuberculosis. J Microbiol Biotechnol 2015; 25: 6: 946-950.</mixed-citation><mixed-citation xml:lang="en">Jang W.S., Kim S., Podder B. et al. Anti-mycobacterial activity of tamoxifen against drug-resistant and intra-macrophage Mycobacterium tuberculosis. J Microbiol Biotechnol 2015; 25: 6: 946-950.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Murakami Y., Fukasawa M., Kaneko Y. et al. Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle. Microb Infect/Institut Pasteur 2013; 15: 1: 45-55.</mixed-citation><mixed-citation xml:lang="en">Murakami Y., Fukasawa M., Kaneko Y. et al. Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle. Microb Infect/Institut Pasteur 2013; 15: 1: 45-55.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Jordan V.C. Tamoxifen as the first successful targeted therapy in cancer: the gift that kept on giving. Breast Cancer Manag 2014; 3: 4: 321-326.</mixed-citation><mixed-citation xml:lang="en">Jordan V.C. Tamoxifen as the first successful targeted therapy in cancer: the gift that kept on giving. Breast Cancer Manag 2014; 3: 4: 321-326.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Singh M.N., Martin-Hirsch P.L., Martin F.L. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med Sci Monitor: Internat Med J Exper Clin Res 2008; 14: 9: RA144-148.</mixed-citation><mixed-citation xml:lang="en">Singh M.N., Martin-Hirsch P.L., Martin F.L. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med Sci Monitor: Internat Med J Exper Clin Res 2008; 14: 9: RA144-148.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
